Nyxoah S.A. (NYXH) Stock Analysis & Winston Score
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Winston Score: 28/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Mixed (8/30)
- Growth: Mixed (6/20)
- Cash Flow: Weak (0/10)
- Stability: Mixed (3/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $1.60
Market Cap: $160M
Sector: Healthcare
Industry: Medical - Specialties
Exchange: NASDAQ
